DDInter743 DDInter927
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Fluconazole {u} (Compound) binds {v} (Gene) CYP3A7
Fluconazole {u} (Compound) upregulates {v} (Gene) MELK
Fluconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Fluconazole {u} (Compound) downregulates {v} (Gene) WFS1
Fluconazole {u} (Compound) causes {v} (Side Effect) Rigors
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Ivacaftor
Fluconazole {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voriconazole
Fluconazole (Compound) binds CYP3A7 (Gene)
Fluconazole (Compound) upregulates MELK (Gene)
Fluconazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Fluconazole (Compound) downregulates WFS1 (Gene)
Fluconazole (Compound) causes Rigors (Side Effect)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole